[ET Net News Agency, 21 December 2021] Sino Biopharmaceutical Limited (01177) said the
group has entered into an exclusive sales agreement of Penpulimab monoclonal antibody with
its associate CTTQ-Akeso (Shanghai) Biomed. Tech. Co., Ltd. (CTTQ-Akeso) and the
associate's shareholder Akeso Biopharma Co., Ltd. (Akeso Biopharma).
Pursuant to the agreement, (i) the group is authorized to be the sole sales agent of
Penpulimab monoclonal antibody injection (PD-1 antibody (AK105) product, the "PD-1
Monoclonal Antibody Product") in China, and is fully responsible for the market
development and product promotion and sales of the PD-1 Monoclonal Antibody Product; and
(ii) the group will receive sales and marketing fees from CTTQ-Akeso, and procure the PD-1
Monoclonal Antibody Product from CTTQ-Akeso.
The PD-1 Monoclonal Antibody Product is co-developed by the group and Akeso Biopharma,
and has been granted marketing approval by the National Medical Products Administration of
China, for the treatment of patients with relapsed or refractory classic Hodgkin's
lymphoma after at least second-line systemic chemotherapy treatment. (RC)